Details of the Drug Combination

General Information of Drug Combination (ID: DCFFC1Z)

• Drug Combination Name: Vinflunine + Topetecan
• Indication: Adenocarcinoma; Status: Investigative [1]
• Component Drugs:
  Vinflunine (DMTJAEP): Small molecular drug
  Topetecan (DMAE6LK): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: SW-620
  Zero Interaction Potency (ZIP) Score: 2.54
  Bliss Independence Score: 4.73
  Loewe Additivity Score: 0.17
  LHighest Single Agent (HSA) Score: 2.93

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Vinflunine

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Approved	[2]

Indication(s) of Topetecan

Disease Entry	ICD 11	Status	REF
Small-cell lung cancer	2C25.Y	Approved	[3]

Topetecan Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
DNA topoisomerase I (TOP1)	TTGTQHC	TOP1_HUMAN	Inhibitor	[4]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adult T acute lymphoblastic leukemia	DC9FFUV	MOLT-4	Investigative	[5]
Anaplastic large cell lymphoma	DCTVW0K	SR	Investigative	[5]

References

• [1] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020671.
• [4] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [5] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.